Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACE Retino
- Development stage
- Unknown
- Lead developer
- Ace Therapeutics
- Modality
- Peptides, Stem Cell Therapies → Cell Therapies
- Administration
- Sublingual
01
Overview
ACE Retino is a sublingual peptide-based therapy developed by Ace Cells Lab Limited for the treatment of various retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal dystrophies. The formulation consists of a complex mixture of peptides derived from fetal tissues and mesenchymal stem cells (MSCs), along with bioactive growth factors. It is designed for systemic absorption via sublingual administration to improve retinal function and structure, enhance visual acuity, and modulate biomarkers such as VEGF, oxidative stress, and inflammatory markers.
- Brand names
- ACE Retino
- Other names
- ACE Retino
Beyond the preview
Go deeper on ACE Retino.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACE Retino.